Status:
TERMINATED
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
PHASE2
Brief Summary
Approximately 25% of people with schizophrenia abuse marijuana. These people may be using marijuana to self-medicate symptoms such as hallucinations (hearing or seeing things that are not heard or see...
Detailed Description
The trial will be a double two period (visit) blind cross-over trial with one arm dronabinol 10 mg one arm a placebo control. The order of doses and placebo will be randomized with the restriction tha...
Eligibility Criteria
Inclusion
- Male and females
- 18 and 50 years of age
- Diagnosis of schizophrenia
- Chronic cannabis users who have used for at least 1 year
- Using cannabis at least once weekly
- Currently being treated with antipsychotic medication
- Must be on a the same dose of antipsychotic medication for at least 3 months.
- Females of childbearing potential must use an adequate form of birth control while participating.
- Participants will be required to have blood pressures greater than 90/60 and less than 140/90.
Exclusion
- Use of illicit drugs other than cannabis
- Any psychiatric hospitalizations within 3 months
- pregnancy in females
- taking clozapine
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01832766
Start Date
June 1 2005
End Date
May 1 2011
Last Update
September 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver
Aurora, Colorado, United States, 80045